| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a6a6caa7f1dad41d1f42a832173f7c0f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4703
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54 |
| filingDate |
2020-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec9222cbcf182defacf6ea6380164b2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d6ab94fbeee63203cf2e8ff61cb2971
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3abdb3f5c8fdd1e652fc166d703c39f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61c5a9128d325067eca060fcc9ed7ec4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc1cf5b38ca8122dad59ee58c45ce072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ff006fcf4b59fed86d2a126918ada81 |
| publicationDate |
2022-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-114174325-A |
| titleOfInvention |
Combination of engineered natural killer cells and engineered T cells for immunotherapy |
| abstract |
Several embodiments of the methods and compositions disclosed herein relate to immune cells engineered to express one of chimeric antigen receptors and/or genetically modified to enhance the efficacy of the immune cells in cellular immunotherapy or Many aspects. Several embodiments relate to genetic modifications that reduce potential side effects of cellular immunotherapy. In several embodiments, compositions of cells are used to achieve rapid and long-term tumor reduction with the potential to reduce or eliminate graft-versus-host effects. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114774364-A |
| priorityDate |
2019-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |